Study wrapper · #1235
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
Editor's note
Post hoc biomarker analyses of phase 2 trials are exploratory by construction, though the false-discovery-rate correction and the use of two independent trials strengthen the picture. The magnitude of the apolipoprotein B and triglyceride-rich particle reductions is what stands out, since those measures track cardiovascular risk more closely than LDL cholesterol alone. The split inflammation result between the diabetes and non-diabetes cohorts is unexplained and worth flagging; none of this substitutes for the outcome trials still ahead for the triple agonist.
Plain-language abstract
This post hoc analysis pulled blood-lipid and inflammation measurements from two randomized placebo-controlled phase 2 trials of retatrutide, one in adults with obesity and type 2 diabetes and one in adults with obesity without diabetes. Retatrutide was associated with large placebo-adjusted reductions across atherogenic lipid measures, including apolipoprotein B down about 21% to 24% and large triglyceride-rich lipoprotein particles down 77% to 84%. Inflammation markers hsCRP and interleukin-6 fell significantly in the group without diabetes but not in the group with diabetes.